Skip to main content

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The TheraP trial

Michael Hofman explains why the TheraP study of LuPSMA versus cabazitaxel in men with metastatic castration-resistant prostate cancer is even more relevant in light of the recently reported CARD trial (4:24).

Read transcript

2021 Genitourinary Cancers Symposium

View our abstract recommendations for the upcoming virtual meeting

Image Credits